NSCLC STAGE IV
Clinical trials for NSCLC STAGE IV explained in plain language.
Never miss a new study
Get alerted when new NSCLC STAGE IV trials appear
Sign up with your email to follow new studies for NSCLC STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Pronged attack on Tough-to-Treat lung cancer
Disease control Not yet recruitingThis study is testing a new combination of two drugs, glecirasib and ivonescimab, for people with advanced non-small cell lung cancer who have a specific genetic change called KRAS G12C and have not yet received treatment. The main goals are to find the safest and most effective …
Matched conditions: NSCLC STAGE IV
Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 01, 2026 21:56 UTC
-
Higher dose tested for lung cancer patients not responding enough to standard treatment
Disease control Not yet recruitingThis study is testing whether increasing the dose of the drug firmonertinib can help patients with advanced lung cancer who have a specific genetic mutation. The trial is for people whose cancer has only stayed stable, not shrunk, after 8 weeks on the standard lower dose. Researc…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC